# 119-s-4692: Homeopathic Drug Product Safety, Quality, and Transparency Act

119-s-4692, Homeopathic Drug Product Safety, Quality, and Transparency Act, is a 119th Congress bill sponsored by Sen. Tuberville, Tommy [R-AL] (R-AL); status introduced; PRIA reads it as touching household money (as of 2026-07-25).

- Canonical: https://policyrisk.com/legislation/119-s-4692
- As of: 2026-07-25
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-s-4692
- Congress: 119
- Title: Homeopathic Drug Product Safety, Quality, and Transparency Act
- Status: introduced
- Introduced: 2026-06-04
- Sponsor: Sen. Tuberville, Tommy [R-AL] (R-AL)
- Cosponsors: 1
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-07-25

## Summary

**Creates a dedicated federal regulatory category for homeopathic drug products.** The bill would set tailored manufacturing, labeling, and safety rules for homeopathic products rather than forcing them through standard drug premarket approval pathways.

## Cosponsors (1)

- Sen. Lee, Mike [R-UT] (R-UT), 2026-06-04T00:00:00.000Z

## Provisions PRIA read

- More safety reports for homeopathics: benefit, low. If enacted, the bill would add homeopathic drug products to the serious adverse event reporting rules. Manufacturers would need to report serious health events for homeopathic products the same way they do for other drugs. This would strengthen postmarket safety monitoring for consumers.
- Testing and safety rules for homeopathics: mixed, medium. If enacted, the bill would exempt finished homeopathic products from the federal lab test that separately verifies identity and strength of each active ingredient. Makers would still have to meet other final specifications, including tests for contaminants and defects. The bill would also require m…
- Labels and claims rules for homeopathics: mixed, medium. If enacted, retail homeopathic products would need to list intended uses for self-limiting conditions and carry the statement that those uses "have not been evaluated by the Food and Drug Administration" and are for traditional homeopathic uses. Any condition-specific claim would have to start with…
- New rules for homeopathic products: mixed, medium. If enacted, the bill would create a distinct statutory pathway for homeopathic drug products and define what counts as a homeopathic ingredient. It would say homeopathic drugs are not subject to the usual FDA premarket approval and would remove current FDA guidance. The bill would also exclude home…

## Related bills

- 119-s-275: Veterans’ Assuring Critical Care Expansions to Support Servicemembers (ACCESS) Act of 2025
- 119-s-4954: Citizenship Act of 2026
- 119-s-3752: SAVE America Act
- 119-s-2907: Chloe Cole Act
- 119-s-1162: SHORT Act
- 119-s-1151: Accountability Through Electronic Verification Act

## Sources
- [119-s-4692 on Congress.gov](https://www.congress.gov/bill/119th-congress/senate-bill/4692)

## Related
- [119-s-275: Veterans’ Assuring Critical Care Expansions to Support Servicemembers (ACCESS)…](https://policyrisk.com/legislation/119-s-275)
- [119-s-4954: Citizenship Act of 2026](https://policyrisk.com/legislation/119-s-4954)
- [119-s-3752: SAVE America Act](https://policyrisk.com/legislation/119-s-3752)
- [119-s-2907: Chloe Cole Act](https://policyrisk.com/legislation/119-s-2907)
- [119-s-1162: SHORT Act](https://policyrisk.com/legislation/119-s-1162)
- [119-s-1151: Accountability Through Electronic Verification Act](https://policyrisk.com/legislation/119-s-1151)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-s-4692 (as of 2026-07-25).